- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04690426
PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers (PROVENT)
July 20, 2022 updated by: Provention Bio, Inc.
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects
Phase 1, first-in-human, randomized, double-blind, placebo-controlled, multiple-dose-escalation study to evaluate the safety, tolerability and immunogenicity of PRV-101, a coxsackie virus B vaccine, in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Thirty two healthy adult subjects will be enrolled into 2 dose cohorts (low-dose and high-dose cohorts, 16 subjects per cohort) and will be randomized in a double-blind manner to PRV-101 or placebo in a 3:1 ratio.
Each subject will receive up to 3 administrations of the study drug (PRV-101 or placebo) at 4-week intervals and will be followed for 24 weeks after the final dose.
Each cohort will start with a sentinel dosing group (2 subjects).
Cohort 2 will commence after safety data from the first 2 doses from all Cohort 1 participants are reviewed.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Turku, Finland
- Clinical Research Services Turku (CRST) Oy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adults, males and females, ages 18 to 45 yrs, with BMI 19 to 30 kg/m2
- Women of childbearing potential must have negative pregnancy test and agree to use an acceptable method of highly effective contraceptive
- Men must either have a vasectomy or agree to use highly effective contraception
Exclusion Criteria:
- Prior or current clinically significant medical illness or disorder
- Has celiac disease or type 1 diabetes or related autoantibodies
- Has active acute or chronic/latent infection, or history of recent serious infection
- Recent acute illness or recent major illness, hospitalization or surgery
- Recent history of alcohol or drug abuse
- Received an experimental antibody or biologic therapy in last 6 months
- Received live, inactivated or subunit virus vaccine or a bacterial vaccine within last 4 weeks
- Intolerance or hypersensitivity to vaccines or vaccine components or has a drug or food allergy or allergic disease requiring medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Cohort 1, Low Dose, Placebo
Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
|
Placebo
|
Experimental: Cohort 1, Low Dose, PRV-101
Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
|
Coxsackie Virus B vaccine
|
Placebo Comparator: Cohort 2, High Dose, Placebo
High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
|
Placebo
|
Experimental: Cohort 2, High Dose, PRV-101
High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
|
Coxsackie Virus B vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of treatment-emergent adverse events (safety and tolerability)
Time Frame: Throughout the 32 weeks of the study
|
Adverse events will be assessed by frequency and criteria for severity (mild, moderate or severe)
|
Throughout the 32 weeks of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of neutralizing antibodies to coxsackie B virus (immunogenicity, efficacy)
Time Frame: Days 1, 29, and 57 and Weeks 12 and 32
|
Proportion of responders (ie, those that seroconvert or have at least a 4-fold increase in neutralizing antibody titers to any of the coxsackie B virus strains as measured by plaque reduction assay using serial serum dilutions)
|
Days 1, 29, and 57 and Weeks 12 and 32
|
Titer of antibodies to coxsackie B virus (immunogenicity, efficacy)
Time Frame: Days 1, 29 and 57 and weeks 12 and 32
|
Mean and peak geometric mean serum IgG titers of antibodies against any of the coxsackie B virus strains, measured by ELISA
|
Days 1, 29 and 57 and weeks 12 and 32
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chief Scientific Officer, CRST Oy
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2020
Primary Completion (Actual)
December 7, 2021
Study Completion (Actual)
December 7, 2021
Study Registration Dates
First Submitted
December 15, 2020
First Submitted That Met QC Criteria
December 27, 2020
First Posted (Actual)
December 30, 2020
Study Record Updates
Last Update Posted (Actual)
July 25, 2022
Last Update Submitted That Met QC Criteria
July 20, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRV-101-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viral; Infection, Coxsackie(Virus)
-
Hospices Civils de LyonRecruiting
-
Northern Orthopaedic Division, DenmarkCompletedTotal Knee Arthritis | Viral; Infection, Slow VirusDenmark
-
University of Wisconsin, MadisonCompletedRespiratory Viral InfectionUnited States
-
Sinovac Biotech Co., LtdWithdrawnInfection, Viral, EnterovirusChina
-
National Cancer Institute (NCI)CompletedViral InfectionsUnited States
-
Sinovac Biotech Co., LtdCompletedInfection, Viral, EnterovirusChina
-
Materia Medica HoldingCompletedAcute Respiratory Viral InfectionRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
QIAGEN Gaithersburg, IncCompletedRespiratory Syncytial Virus Infections | Influenza A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infection Due to Human Parainfluenza Virus 1 | Parainfluenza Type 2 | Parainfluenza Type 3 | Parainfluenza Type 4 | Human Metapneumovirus A/B | Coxsackie Virus/Echovirus | Adenovirus Types B/C/E | Coronavirus Subtypes 229E and other conditionsUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States